Search results

I think this sentence shows how they view this issue: EDIT: So they think that the biomedical model is causing patients to exaggerate their symptoms. I suspect that might also be the reason why Busse got involved in ME/CFS research and criticised the NICE guidance quite aggressively.

I don't understand because burnout is defined as being work-related. The WHO states: https://www.who.int/news/item/28-05-2019-burn-out-an-occupational-phenomenon-international-classification-of-diseases So this mainly shows that the authors of this study did not understand the concept of...

Yes that seems about 10-20 times too large.

The point was so clear that it seems that Larun et al. are intentionally misrepresenting it.

It states: So: we the reviewers determined that our review is well-conducted?

I also don't get that if the main problem is that the drug is really expensive, then why would you include 86 participants on the drug, and nobody on a placebo (which costs virtually nothing).

The paper states: But as someone pointed out to me on Twitter, table 1 shows that 'no change in symptoms' (n = 17) was more common than 'financially unable' (n = 10). So lack of perceived benefit seems to be the primary, not a secondary reason for dropout?

I also think Carson has never done any research on ME/CFS, yet he has been able to comment as an SMC expert on multiple ME/CFS studies. For example: expert reaction to cytokines for Chronic Fatigue Syndrome | Science Media Centre expert reaction to study linking higher levels of antibodies...

I also don't get this. The only statement I see is: "Evidence that there is a large number of replicated and diverse blood biomarkers that differentiate between ME/CFS cases and controls should now dispel any lingering perception that ME/CFSis caused by deconditioning and exercise intolerance...

Because they controlled the FDR at 0.05, the expected proportions of false positives among the 116 significant features is approximately 6 (not 150).

This method controls the false discovery rate (FDR) at 0.05, which is mentioned multiple times in the paper and graphs. It means that among the significant findings, the expected proportion of false positives (the false discoveries) is only 5%. It's not that complicated and standard in large...

The commentary by Prof Kevin McConway (Emeritus Professor of Applied Statistics) seems quite sensible.

I meant chronic unexplained widespread pain which I think is what the fibromyalgia diagnosis is mostly used for (this may differ pre region though). Seems to occur in a similar population to ME/CFS (mostly adult females), and shows some overlap in symptoms but the energy limitations, PEM, POTS...

8% seems far too high but my impression is that it is at least double that of ME/CFS.

I once wrote this: https://www.s4me.info/threads/central-sensitization-a-matter-of-concern.5346/

Thanks for the tag. I wasn't aware of this Italian study. Had a quick look and it seems interesting that the response between melatonin and agomelatonine was so different.

The reason for posting this is that the Dutch government research funder ZonMw has funded a stud on this drug (sonlicromanol) for Long Covid patients. It's led by Michele van Vugt at Amsterdam University...

Abstract Mitochondrial disease incorporates a group of rare conditions with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it...

Agree with others that this study design isn't able to show what the real effect is, but it does give a ceiling to how large the effect might be. I'm assuming that the 40 patients who kept paying for the drug had a better response than the sample as a whole (the paper says that a common reason...

The Nevada study which they used as a validation cohort was originally published in 2016 and discussed here (it highlighted GRIK3 which plays a role in neurotransmission). Genome-wide association analysis identifies genetic variations in subjects with [ME/CFS], 2016, Schlauch et al | Science for ME